newsfilter
← Latest News
PR Newswire·

Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol

  • Eocene Ltd. reports a novel Aramchol formulation using FDA-approved lipids developed via Barcode Nanotech's proprietary tumor-targeting LNP platform.
  • The new LNP formulation redirects Aramchol biodistribution to the tumor microenvironment (TME) of liver & GI tumors to selectively inhibit cells driving fibrosis.
  • Targeting fibrotic TME cells aims to enhance the efficacy of immunotherapy & standard-of-care treatments for more patients while maintaining minimal toxicity.
  • Previous trials (ARREST & ARMOR) showed orally formulated Aramchol improved liver fibrosis in NASH/MASH patients.
  • CEO Allen Baharaff states fibrosis creates an immune-suppressive barrier that limits immunotherapy duration & effectiveness.
  • Barcode CEO Ronen Eavri confirms the use of their AI-based screening & lipid library to direct Aramchol to TME cells in liver & GI cancers.
  • Eocene is a GI-focused company developing Aramchol for liver disease & oncology & operates Colospan Ltd., a medtech subsidiary with the FDA-designated CG-100 device.
  • Barcode Nanotech utilizes a multiplexed discovery platform combining in silico design, AI, & in vivo barcoding to optimize lipid-based nanoparticles for specific organ targeting.
Company
Eocene
Keywords
Eocene